Studies on the pharmacology of alpha-methyl-3,4-dihydroxyphenylalanine (alpha-methyl-dopa) and alpha-methylnorepinephrine. II.
D006916:5-Hydroxytryptophan / Q000494:pharmacology; D000818:Animals; D001143:Arousal / Q000187:drug effects; D001921:Brain / Q000187:drug effects*; D002415:Cats; D002421:Caudate Nucleus / Q000187:drug effects; D010856:Columbidae; D004295:Dihydroxyphenylalanine / Q000494:pharmacology; D004558:Electric Stimulation; D004569:Electroencephalography; D006624:Hippocampus / Q000187:drug effects; D007267:Injections; D008238:Lysergic Acid Diethylamide / Q000494:pharmacology; D008750:Methyldopa / Q000008:administration & dosage / Q000494:pharmacology*; D051379:Mice; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology; D009526:Nialamide / Q000494:pharmacology; D009647:Normetanephrine / Q000008:administration & dosage / Q000494:pharmacology*; D011817:Rabbits; D012154:Reticular Formation / Q000502:physiology; D012890:Sleep / Q000187:drug effects; D013016:Sound
D008996:Monoamine Oxidase Inhibitors; D009647:Normetanephrine; D008750:Methyldopa; D004295:Dihydroxyphenylalanine; D008238:Lysergic Acid Diethylamide; D006916:5-Hydroxytryptophan; D009526:Nialamide